Search

Your search keyword '"Keyzner, Alla"' showing total 10 results
Start Over Author "Keyzner, Alla" Journal blood
10 results on '"Keyzner, Alla"'

1. Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Author

Jain, Tania, primary, Tsai, Hua-Ling, additional, Elmariah, Hany, additional, Vachhani, Pankit, additional, Karantanos, Theodoros, additional, Wall, Sarah A, additional, Gondek, Lukasz P., additional, Bashey, Asad, additional, Keyzner, Alla, additional, Grunwald, Michael R., additional, Abedin, Sameem, additional, Nadiminti, Kalyan VG, additional, Iqbal, Madiha, additional, Gerds, Aaron T., additional, Viswabandya, Auro, additional, McCurdy, Shannon R, additional, Al Malki, MHD Monzr M., additional, Varadhan, Ravi, additional, Ali, Haris, additional, Gupta, Vikas, additional, Jones, Richard J., additional, and Otoukesh, Salman, additional

Published
2022
Full Text
View/download PDF

2. Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Author

Balev, Metodi, primary, Zubizarreta, Nicole, additional, Bresnahan, Erin, additional, Feld, Jonathan, additional, Kremyanskaya, Marina, additional, Keyzner, Alla, additional, Shih, Alan H., additional, Marcellino, Bridget K, additional, Silverman, Lewis R., additional, Bar-Natan, Michal, additional, Mascarenhas, John, additional, and Tremblay, Douglas, additional

Published
2022
Full Text
View/download PDF

4. No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Author

Milano, Filippo, primary, Rezvani, Andrew R, primary, Kurtzberg, Joanne, primary, Karanes, Chatchada, primary, Gutman, Jonathan A, primary, Duncan, Christine, primary, Keyzner, Alla, primary, Hanna, Rabi, primary, Marmon, Tonya Kimberly, primary, Dahlberg, Ann, primary, and Delaney, Colleen, primary

Published
2019
Full Text
View/download PDF

5. Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Author

Tremblay, Douglas, primary, Madero-Marroquin, Rafael, additional, Lancman, Guido, additional, Coltoff, Alexander, additional, Feld, Jonathan, additional, Caro, Jessica, additional, Zubizarreta, Nicole, additional, Kremyanskaya, Marina, additional, Keyzner, Alla, additional, Bar-Natan, Michal, additional, Navada, Shyamala C., additional, Silverman, Lewis R., additional, Gabrilove, Janice L., additional, and Mascarenhas, John, additional

Published
2019
Full Text
View/download PDF

6. The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis

Author

Lancman, Guido, primary, Miller, Kathleen, additional, Li, Shuli, additional, Ho, Vincent T., additional, Fathi, Amir T., additional, Chen, Yi-Bin, additional, Keyzner, Alla, additional, Tremblay, Douglas, additional, Geevarghese, Anita, additional, Chatterjee, Prapti, additional, Hoffman, Ronald, additional, Mascarenhas, John, additional, and Hobbs, Gabriela S., additional

Published
2018
Full Text
View/download PDF

8. Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies

Author

Iancu-Rubin, Camelia, primary, Fong, Helen, additional, Mosoyan, Goar, additional, Patel, Ami, additional, Sabado, Rachel, additional, Marcia, Meseck, additional, Moshier, Erin, additional, Ozbek, Umut, additional, Keyzner, Alla, additional, Bhardwaj, Nina, additional, McNiece, Ian K., additional, Tong, Jay, additional, and Hoffman, Ronald, additional

Published
2016
Full Text
View/download PDF

9. Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Author

Al Malki, Monzr M., Keyzner, Alla, Suh, Hyung Chan, Matin, Aasiya, Buonomo, Erica, Wang, Yun, Abelowitz, Nina, Murray, Jim, Macbeath, Gavin, Barton, Debora, Chattopadhyay, Shrikanta, and Reshef, Ran

Abstract

Introduction: To date, engineered T cell therapies have not proven effective for non-B cell hematologic malignancies due to a lack of antigens that spare healthy myeloid cells. Allogeneic hematopoietic cell transplantation (HCT) remains the best curative option for these malignancies, yet ~40% of patients relapse post-HCT with high mortality after relapse. A potential solution to prevent relapse is to target hematopoietic lineage-specific minor histocompatibility antigens (MiHAs) that are genetically mismatched between HCT patients and donors. These mismatches enable engineered T cells to selectively eliminate residual patient hematopoietic cells, normal or malignant, and spare donor cells. TSC-100 and TSC-101 are allogeneic, donor derived T-cell receptor-engineered T (TCR-T) cells that target MiHAs HA-1 and HA-2 respectively, both presented on HLA-A*02:01. By choosing HCT patients who are HLA-A*02:01 positive and donors who are either HLA-A*02:01 or MiHA negative, TSC-100 or TSC-101 are designed to eliminate residual patient hematopoietic cells post-HCT and thus prevent relapse (figure).

Published
2023
Full Text
View/download PDF

10. Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Author

Ajufo, Helen, Derkach, Andriy, Rampal, Raajit K., Famulare, Christopher, Nemirovsky, David, Chervin, Jordan, Ho, Vincent, Gupta, Vikas, Viswabandya, Auro, Deeg, H. Joachim, Monahan, Tim, Jain, Tania, Jones, Richard J., Palmer, Jeanne, Gerds, Aaron T., Keyzner, Alla, Lagdameo, Jonathan, Gomez-Arteaga, Alexandra, Van Besien, Koen, Podoltsev, Nikolai A., Puzo, Christian, Kosuri, Satyajit, Amanam, Idoroenyi, and Tamari, Roni

Abstract

Introduction:Myelofibrosis (MF) is a clonal hematologic malignancy characterized by constitutive JAK-STAT activation and aberrant cytokine signaling. Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative therapy in MF. The contribution of disease-, patient- and donor-related factors to allo-HCT outcomes remains to be fully elucidated, as well as the presence of somatic mutations in genes such as ASXL1, EZH2, SRSF2, U2AF1and IDH1/2which are associated with worse prognosis in MF patients (pts). In this large multi- center retrospective analysis, we aimed to study the impact of clinical and molecular mutations on transplant outcomes.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results